Why the Rhythm (ASX:RHY) share price again reached a new all-time record today

The Rhythm Biosciences Ltd (ASX: RHY) has risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.

It seems like Rhythm Biosciences Ltd (ASX: RHY) can do no wrong by investors at the moment. Today, the company's shares have risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.

During early morning trade, the Rhythm share price rose to an intraday high of $1.38. However, some profit taking have led its share to slightly retreat to, at the time of writing, $1.35, up 7.14%.

hand on touch screen lit up by a share price chart moving higher

Image source: Getty Images

What's driving the Rhythm share price to new highs?

The Rhythm share price is breaking new highs as investors are fighting to get a hold of its shares.

In its announcement, Rhythm advised that its global manufacturer, Biotem, has completed initial ColoSTAT prototype test kits. The small-scale production of ColoSTAT devices commenced in December, with delivery fulfilled ahead of schedule later that month.

Having received the first prototype units, Rhythm began testing the performance of ColoSTAT test kits with cancerous and healthy blood samples. The company noted that full testing is underway and will form Study 6, due to be completed by March 2021.

Rhythm noted that early quality assurance and performance test work is consistent with its own prototype test results.

Room for improvement

In addition to the assembly of ColoSTAT, the company stated that it has continued its efforts in advancing the technology behind the test kit. The current version, which is considered far superior than the current market standard faecal test, is undergoing improvements.

Rhythm advised it has allocated extra resources to its algorithm and software development division to enhance the existing technology on offer. As more samples arrive, it will use this to create a larger dataset to assess any performance changes made. New developments will be applied to study 7 and onward.

CEO commentary

Rhythm CEO, Mr Glenn Gilbert, hailed the milestone achievement, saying:

The objective of design transfer of the core ColoSTAT technology to our global manufacturer, Biotem, is to demonstrate that they are able to produce, in a commercial setting, the same consistent and high performing ColoSTAT test kit that Rhythm had achieved in lab.

The early view on the performance of the test kits manufactured by Biotem provides further confidence on our underlying technology that will drive the success of ColoSTAT into the future.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »

Army man holding a drone while the army woman holds the remote control.
52-Week Lows

Can DroneShield shares rebound from fresh 52-week low, or is there more downside ahead?

Investors have fallen out of love with the counter-drone operator’s shares.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Frustrated man looking exhausted while sitting at his desk with his laptop and carrying his glasses in his hand.
ASX Share Market News

5 things to watch on the ASX 200 on Tuesday

It looks set to be a tough session for Aussie investors.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

rubbish bins
Opinions

I've always loved Wesfarmers shares. But after a trip to Kmart, I'm not so sure

A weekend trip took some gloss off this stock.

Read more »